The role of T cells in the development of cardiovascular disease in HIV-infected patients

Atherosclerosis

Volumn 237, Issue 1, 2014, Pages 92-98

  Krikke, M ^a   van Lelyveld, S F L ^a   Tesselaar, K ^a   Arends, J E ^a   Hoepelman, I M ^a   Visseren, F L J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Atherosclerosis; Cardiovascular disease; CD4+ T cells; CD8+ T cells; Coagulation markers; Endothelial markers; HIV; HIV infection; Immune activation; Inflammatory markers; Monocyte activation; Monocytes; T cell activation

Indexed keywords

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DISEASE COURSE; DISEASE MARKER; EPIDEMIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATORY CELL; INFLAMMATORY DISEASE; RETROVIRUS INFECTION; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ANIMAL; BLOOD; COMORBIDITY; COMPLICATION; CYTOLOGY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; IMMUNOLOGY; INFLAMMATION; LYMPHOCYTE ACTIVATION; MOUSE;

ANTIINFLAMMATORY AGENT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; COMORBIDITY; HIV INFECTIONS; HUMANS; INFLAMMATION; LYMPHOCYTE ACTIVATION; MICE; T-LYMPHOCYTES;

EID: 84907865968     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.08.054     Document Type: Review

References (99)

1. Helleberg M., Kronborg G., Larsen C.S., Pedersen G., Pedersen C., Gerstoft J., et al. Causes of death among Danish HIV patients compared with population controls in the period 1995-2008. Infection 2012, 40(6):627-634.
2. Porter K., Babiker A., Bhaskaran K., Darbyshire J., Pezzotti P., Walker A.S. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 2003, 362(9392):1267-1274.
3. Smit C., Geskus R., Walker S., Sabin C., Coutinho R., Porter K., et al. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS 2006, 20(5):741-749.
4. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008, 372(9635):293-299.
5. Bhaskaran K., Hamouda O., Sannes M., Boufassa F., Johnson A.M., Lambert P.C., et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAm Med Assoc 2008, 300(1):51-59.
6. Lohse N., Hansen A.B., Pedersen G., Kronborg G., Gerstoft J., Sørensen H.T., et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007, 146(2):87-95.
7. van Assen S., Danner S., Ghani A.C., Gras L., Anderson R.M., De W.F. Mortality in patients with successful initial response to highly active antiretroviral therapy is still higher than in non-HIV-infected individuals. JAcquir Immune Defic Syndr 2005, 40(2):212-218.
8. Deeks S.G. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 2011, 62:141-155.
9. Mocroft A., Reiss P., Gasiorowski J., Ledergerber B., Kowalska J., Chiesi A., et al. Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. JAcquir Immune Defic Syndr 2010, 55(2):262-270.
10. Neuhaus J., Angus B., Kowalska J.D., La Rosa A., Sampson J., Wentworth D., et al. Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. AIDS 2010, 24(5):697-706.
11. Wada N., Jacobson L.P., Cohen M., French A., Phair J., Munoz A. Cause-specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome-negative individuals followed simultaneously in long-term cohort studies, 1984-2008. Am J Epidemiol 2013, 177(2):116-125.
12. Currier J.S., Taylor A., Boyd F., Dezii C.M., Kawabata H., Burtcel B., et al. Coronary heart disease in HIV-infected individuals. JAcquir Immune Defic Syndr 2003, 33(4):506-512.
13. Triant V.A., Lee H., Hadigan C., Grinspoon S.K. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. JClin Endocrinol Metab 2007, 92(7):2506-2512.
14. Cruse B., Cysique L.A., Markus R., Brew B.J. Cerebrovascular disease in HIV-infected individuals in the era of highly active antiretroviral therapy. JNeurovirol 2012, 18(4):264-276.
15. Ho J.E., Hsue P.Y. Cardiovascular manifestations of HIV infection. Heart 2009, 95(14):1193-1202.
16. Duval X., Baron G., Garelik D., Villes V., Dupré T., Leport C., et al. Living with HIV, antiretroviral treatment experience and tobacco smoking: results from a multisite cross-sectional study. Antivir Ther 2008, 13(3):389-397.
17. Braithwaite R.S., Conigliaro J., Roberts M.S., Shechter S., Schaefer A., McGinnis K., et al. Estimating the impact of alcohol consumption on survival for HIV+ individuals. AIDS Care 2007, 19(4):459-466.
18. Baker J.V., Lundgren J.D. Cardiovascular implications from untreated human immunodeficiency virus infection. Eur Heart J 2011, 32(8):945-951.
19. Hsue P.Y., Deeks S.G., Hunt P.W. Immunologic basis of cardiovascular disease in HIV-infected adults. JInfect Dis 2012, 205(Suppl.):S375-S382.
20. Ipp H., Zemlin A. The paradox of the immune response in HIV infection: when inflammation becomes harmful. Clin Chim Acta 2013, 416:96-99.
21. WHO The top 10 causes of death 2013, Available from:. http://www.who.int/mediacentre/factsheets/fs310/en/index.html.
22. Go A.S., Mozaffarian D., Roger V.L., Benjamin E.J., Berry J.D., Blaha M.J., et al. Heart disease and stroke statistics-2014 update: a report from the American heart association. Circulation 2013.
23. WHO Cardiovascular disease facts 2013, Available from:. http://www.who.int/mediacentre/factsheets/fs317/en/index.html.
24. Schram A., Labonté R., Sanders D. Urbanization and international trade and investment policies as determinants of noncommunicable diseases in sub-saharan Africa. Prog Cardiovasc Dis 2013, 56(3):281-301.
25. WHO HIV/AIDS facts 2013, Available from:. http://www.who.int/mediacentre/factsheets/fs360/en/index.html.
26. Fauci A.S., Pantaleo G., Stanley S., Weissman D. Immunopathogenic mechanisms of HIV infection. Ann Intern Med 1996, 124(7):654-663.
27. Dolin R., Masur H., Saag M. AIDS therapy 2008, 559-578. Third. K. Bowler, T. Nguyen (Eds.).
28. Mcmichael A.J., Ch B., Ph D., Haynes B.F. Acute HIV-1 infection 2011.
29. McMichael A.J., Borrow P., Tomaras G.D., Goonetilleke N., Haynes B.F. The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol 2010, 10(1):11-23.
30. Brenchley J.M., Price D.A., Douek D.C. HIV disease: fallout from a mucosal catastrophe?. Nat Immunol 2006, 7(3):235-239.
31. Hunt P.W. HIV and inflammation: mechanisms and consequences. Curr HIV/AIDS Rep 2012, 9(2):139-147.
32. Deayton J.R., Prof Sabin C.A., Johnson M.A., Emery V.C., Wilson P., Griffiths P.D. Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy. Lancet 2004, 363(9427):2116-2121.
33. Hsue P.Y., Ordovas K., Lee T., Reddy G., Gotway M., Schnell A., et al. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. AIDS 2006, 20(18):2275-2283.
34. Parrinello C.M., Sinclair E., Landay A.L., Lurain N., Sharrett A.R., Gange S.J., et al. Cytomegalovirus immunoglobulin G antibody is associated with subclinical carotid artery disease among HIV-infected women. JInfect Dis 2012, 205(12):1788-1796.
35. Sheth P.M., Sunderji S., Shin L.Y., Rebbapragada A., Huibner S., Kimani J., et al. Coinfection with herpes simplex virus type 2 is associated with reduced HIV-specific T cell responses and systemic immune activation. JInfect Dis 2008, 197(10):1394-1401.
36. Hazenberg M.D., Hamann D., Schuitemaker H., Miedema F. Tcell depletion in HIV-1 infection: how CD4+ T cells go out of stock. Nat Immunol 2000, 1(4):285-289.
37. Giorgi J.V., Lyles R.H., Matud J.L., Yamashita T.E., Mellors J.W., Hultin L.E., et al. Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. JAcquir Immune Defic Syndr 2002, 29(4):346-355.
38. Gazzola L., Tincati C., Bellistri G.M., Monforte A., Marchetti G. The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options. Clin Infect Dis 2009, 48(3):328-337.
39. Florence E., Lundgren J., Dreezen C., Fisher M., Kirk O., Blaxhult A., et al. Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIV Med 2003, 4(3):255-262.
40. Kaufmann G.R., Furrer H., Ledergerber B., Perrin L., Opravil M., Vernazza P., et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis 2005, 41(3):361-372.
41. van Lelyveld S.F., Gras L., Kesselring A., Zhang S., De Wolf F., Wensing A.M., et al. Long-term complications in patients with poor immunological recovery despite virological successful HAART in Dutch ATHENA cohort. AIDS 2012, 26(4):465-474.
42. Nairn R., Helbert M. Immunology for medical students. Second edi 2007.
43. Hunt P.W., Brenchley J., Sinclair E., McCune J.M., Roland M., Page-Shafer K., et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. JInfect Dis 2008, 197(1):126-133.
44. Hunt P.W., Martin J.N., Sinclair E., et al. Tcell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. JInfect Dis 2003, 187(10):1534-1543.
45. Lederman M.M., Calabrese L., Funderburg N.T., et al. Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. JInfect Dis 2011, 204(8):1217-1226.
46. Funderburg N.T., Zidar D.A., Shive C., et al. Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndrome. Blood 2012, 120(23):4599-4608.
47. Fitch K.V., Srinivasa S., Abbara S., et al. Noncalcified coronary atherosclerotic plaque and immune activation in HIV-infected women. JInfect Dis 2013, 208(11):1737-1746.
48. Barbour J.D., Jalbert E.C., Chow D.C., et al. Reduced CD14 expression on classical monocytes and vascular endothelial adhesion markers independently associate with carotid artery intima media thickness in chronically HIV-1 infected adults on virologically suppressive anti-retroviral therapy. Atherosclerosis 2014, 232(1):52-58.
49. Burdo T.H., Lo J., Abbara S., et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. JInfect Dis 2011, 204(8):1227-1236.
50. Rogacev K.S., Cremers B., Zawada A.M., et al. CD14++CD16+ monocytes independently predict cardiovascular events: a cohort study of 951 patients referred for elective coronary angiography. JAm Coll Cardiol 2012, 60(16):1512-1520.
51. Mendez-Lagares G., Garcia-Perganeda A., del Pozo-Balado del M., et al. Differential alterations of the CD4 and CD8 T cell subsets in HIV-infected patients on highly active antiretroviral therapy with low CD4 T cell restoration. JAntimicrob Chemother 2012, 67(5):1228-1237.
52. Armah K.A., McGinnis K., Baker J., Gibert C., Butt A.A., Bryant K.J., et al. HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation. Clin Infect Dis 2012, 55(1):126-136.
53. Arildsen H., Sorensen K.E., Ingerslev J.M., Ostergaard L.J., Laursen A.L. Endothelial dysfunction, increased inflammation, and activated coagulation in HIV-infected patients improve after initiation of highly active antiretroviral therapy. HIV Med 2013, 14(1):1-9.
54. Calmy A., Gayet-Ageron A., Montecucco F., Nguyen A., Mach F., Burger F., et al. HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS 2009, 23(8):929-939.
55. Kuller L.H., Tracy R., Belloso W., De Wit S., Drummond F., Lane H.C., et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008, 5(10):e203.
56. Duprez D.A., Neuhaus J., Kuller L.H., Tracy R., Belloso W., De Wit S., et al. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One 2012, 7(9):e44454.
57. Baker J.V., Neuhaus J., Duprez D., Kuller L.H., Tracy R., Belloso W.H., et al. Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. JAcquir Immune Defic Syndr 2011, 56(1):36-43.
58. Sandler N.G., Wand H., Roque A., Law M., Nason M.C., Nixon D.E., et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. JInfect Dis 2011, 203(6):780-790.
59. Mangili A., Polak J.F., Quach L.A., Gerrior J., Wanke C.A. Markers of atherosclerosis and inflammation and mortality in patients with HIV infection. Atherosclerosis 2011, 214(2):468-473.
60. Miwa K., Tanaka M., Okazaki S., Furukado S., Sakaguchi M., Mochizuki H., et al. Association between interleukin-6 levels and first-ever cerebrovascular events in patients with vascular risk factors. Arterioscler Thromb Vasc Biol 2013, 33(2):400-405.
61. Ridker P.M., Rifai N., Stampfer M.J., Hennekens C.H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000, 101(15):1767-1772.
62. Lo J., Plutzky J. The biology of atherosclerosis: general paradigms and distinct pathogenic mechanisms among HIV-infected patients. JInfect Dis 2012, 205(Suppl.):S368-S374.
63. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. NEngl J Med 2000, 342(12):836-843.
64. Kaptoge S., Di Angelantonio E., Lowe G., Pepys M.B., Thompson S.G., Collins R., et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010, 375(9709):132-140.
65. Di Angelantonio E., Gao P., Pennells L., Kaptoge S., Caslake M., Thompson A., et al. Lipid-related markers and cardiovascular disease prediction. JAm Med Assoc 2012, 307(23):2499-2506.
66. Aukrust P., Müller F., Ueland T., Berget T., Aaser E., Brunsvig A., et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 1999, 100(6):614-620.
67. Lindahl B., Toss H., Siegbahn A., Venge P., Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC study group. Fragmin during instability in coronary artery disease. NEngl J Med 2000 Oct 19, 343(16):1139-1147.
68. Tabib A., Leroux C., Mornex J.F., Loire R. Accelerated coronary atherosclerosis and arteriosclerosis in young human-immunodeficiency-virus-positive patients. Coron Artery Dis 2000, 11(1):41-46.
69. Kwiatkowska W.1, Knysz B., Drelichowska-Durawa J., Czarnecki M., Gasiorowski J., Biłyk E., et al. Subclinical carotid atherosclerosis and cardiovascular risk factors in HIV-infected patients. Postep Hig Med Dosw(Online) 2011, 65:770-783.
70. Hsue P.Y., Ordovas K., Lee T., Reddy G., Gotway M., Schnell A., et al. Carotid intima-media thickness among human immunodeficiency virus-infected patients without coronary calcium. Am J Cardiol 2012, 109(5):742-747.
71. Kaplan R.C., Sinclair E., Landay A.L., Lurain N., Sharrett A.R., Gange S.J., et al. Tcell activation and senescence predict subclinical carotid artery disease in HIV-infected women. JInfect Dis 2011, 203(4):452-463.
72. Merlini E.1, Luzi K., Suardi E., Barassi A., Cerrone M., Martínez J.S., et al. T-cell phenotypes, apoptosis and inflammation in HIV+ patients on virologically effective cART with early atherosclerosis. PLoS One 2012, 7(9):e46073.
73. Baker J.V., Henry W.K., Patel P., Bush T.J., Conley L.J., Mack W.J., et al. Progression of carotid intima-media thickness in a contemporary human immunodeficiency virus cohort. Clin Infect Dis 2011, 53(8):826-835.
74. Kaplan R.C., Sinclair E., Landay A.L., Lurain N., Sharrett A.R., Gange S.J., et al. Tcell activation predicts carotid artery stiffness among HIV-infected women. Atherosclerosis 2011, 217(1):207-213.
75. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999, 138(5 Pt 2):S419-S420.
76. Andersson J., Libby P., Hansson G.K. Adaptive immunity and atherosclerosis. Clin Immunol 2010, 134(1):33-46.
77. Paiardini M., Muller-Trutwin M. HIV-associated chronic immune activation. Immunol Rev 2013, 254(1):78-101.
78. Libby P., Ridker P.M., Hansson G.K. Progress and challenges in translating the biology of atherosclerosis. Nature 2011, 473(7347):317-325.
79. Jonasson L., Holm J., Skalli O., Bondjers G., Hansson G.K. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis 1986, 6(2):131-138.
80. Zhou X., Stemme S., Hansson G.K. Evidence for a local immune response in atherosclerosis. CD4+ T cells infiltrate lesions of apolipoprotein-E-deficient mice. Am J Pathol 1996, 149(2):359-366.
81. Kyaw T., Winship A., Tay C., Kanellakis P., Hosseini H., Cao A., et al. Cytotoxic and proinflammatory CD8+ T lymphocytes promote development of vulnerable atherosclerotic plaques in apoE-deficient mice. Circulation 2013, 127(9):1028-1039.
82. De Palma R., Del Galdo F., Abbate G., Chiariello M., Calabró R., Forte L. Patients with acute coronary syndrome show oligoclonal T-cell recruitment within unstable plaque: evidence for a local, intracoronary immunologic mechanism. Circulation 2006, 113(5):640-646.
83. Ren Z., Yao Q., Chen C. HIV-1 envelope glycoprotein 120 increases intercellular adhesion molecule-1 expression by human endothelial cells. Lab Invest 2002, 82(3):245-255.
84. Duan M., Yao H., Hu G., Chen X., Lund A.K., Buch S.H.I.V. Tat induces expression of ICAM-1 in HUVECs: implications for miR-221/-222 in HIV-associated cardiomyopathy. PLoS One 2013, 8(3):e60170.
85. Matsushita K., van der Velde M., Astor B.C., Woodward M., Levey A.S., de Jong P.E., et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010, 375(9731):2073-2081.
86. Serrano-Villar S., Estrada V., Gómez-Garre D., Ávila M., Fuentes-Ferrer M., Sánchez-Parra C., et al. Incipient renal impairment as a predictor of subclinical atherosclerosis in HIV-infected patients. JAcquir Immune Defic Syndr 2012, 59(2):141-148.
87. Preis S.R., Hwang S.J., Coady S., Pencina M.J., D'Agostino R.B., Savage P.J., et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham heart study, 1950 to 2005. Circulation 2009, 119(13):1728-1735.
88. Haffner S.M., Lehto S., Ronnemaa T., Pyorala K., Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. NEngl J Med 1998, 339(4):229-234.
89. Giubilato S., Liuzzo G., Brugaletta S., Pitocco D., Graziani F., Smaldone C., et al. Expansion of CD4+CD28null T-lymphocytes in diabetic patients: exploring new pathogenetic mechanisms of increased cardiovascular risk in diabetes mellitus. Eur Heart J 2011, 32(10):1214-1226.
90. Alviggi L., Johnston C., Hoskins P.J., Tee D.E., Pyke D.A., Leslie R.D., et al. Pathogenesis of insulin-dependentdiabetes: a role for activated T lymphocytes. Lancet 1984, 2(8393):4-6.
91. Engelbertsen D., To F., Dunér P., Kotova O., Söderberg I., Alm R., et al. Increased inflammation in atherosclerotic lesions of diabetic akita-LDLr(-)/(-) mice compared to nondiabetic LDLr(-)/(-) mice. Exp Diabetes Res 2012, 2012. 17616:176162.
92. Deeks S.G., Tracy R., Douek D.C. Systemic effects of inflammation on health during chronic HIV infection. Immunity 2013, 39(4):633-645.
93. Ganesan A., Crum-Cianflone N., Higgins J., Qin J., Rehm C., Metcalf J., et al. High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. JInfect Dis 2011, 203(6):756-764.
94. O'Brien M., Montenont E., Hu L., Nardi M.A., Valdes V., Merolla M., et al. Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: a pilot study. JAcquir Immune Defic Syndr 2013, 63(3):280-288.
95. Cahn P., Ruxrungtham K., Gazzard B., Diaz R.S., Gori A., Kotler D.P., et al. The immunomodulatory nutritional intervention NR100157 reduced CD4+ T-cell decline and immune activation: a 1-year multicenter randomized controlled double-blind trial in HIV-infected persons not receiving antiretroviral therapy (The BITE Study). Clin Infect Dis 2013, 57(1):139-146.
96. Gori A., Rizzardini G., Van't Land B., Amor K.B., van Schaik J., Torti C., et al. Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: results of the "COPA" pilot randomized trial. Mucosal Immunol 2011, 4(5):554-563.
97. Cipriani S., Francisci D., Mencarelli A., Renga B., Schiaroli E., D'Amore C., et al. Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice. Circulation 2013, 127(21):2114-2124.
98. van Wanrooij E.J., Happé H., Hauer A.D., de Vos P., Imanishi T., Fujiwara H., et al. HIV entry inhibitor TAK-779 attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2005, 25(12):2642-2647.
99. Jain V., Hartogensis W., Bacchetti P., Hunt P.W., Hatano H., Sinclair E., et al. Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. JInfect Dis 2013, 208(8):1202-1211.